TY - JOUR
T1 - Perampanel may represent an effective treatment for the prevention of migraine comorbid with epilepsy
AU - Fernandes, Mariana
AU - Dono, Fedele
AU - Dainese, Filippo
AU - Renna, Rosaria
AU - Consoli, Stefano
AU - Gaspari, Caterina
AU - Izzi, Francesca
AU - Pagliuca, Mauro
AU - Placidi, Fabio
AU - Biagio Mercuri, Nicola
AU - Liguori, Claudio
N1 - Publisher Copyright:
© 2021 Elsevier Inc.
PY - 2021/12
Y1 - 2021/12
N2 - Introduction: Migraine is a common comorbidity in patients with epilepsy. Considering the proven associations and the common pathophysiological features linking epilepsy and migraine, some anti-seizure medications (ASMs) have been considered as a treatment for both disorders. This study aimed at assessing both the effectiveness of perampanel (PER) on epileptic seizures and migraine attacks in patients with epilepsy and comorbid migraine, as well as the reduction in the monthly mean rate usage of rescue migraine medications. Methods: This observational, multi-centre study included adult patients with epilepsy and comorbid migraine who started PER to better control epileptic seizures and who were followed up for 12 months. Results: Thirty-one patients were included (mean age 40.13 ± 13.13 years; 67.0% female). At the 12-month follow-up visit, 27 patients were continuing PER concomitantly with 1 (45.2%) or 2 ASMs (54.8%). A significant reduction in epileptic seizures, migraine attacks, and the monthly use of rescue migraine medications between baseline and both 6- and 12-month follow-up visits was documented. Conclusion: PER demonstrated good effectiveness in reducing both epileptic seizures and migraine attacks in patients with comorbid epilepsy and migraine. Future studies with possibly larger samples are needed to evaluate the efficacy of PER in migraine other than epilepsy.
AB - Introduction: Migraine is a common comorbidity in patients with epilepsy. Considering the proven associations and the common pathophysiological features linking epilepsy and migraine, some anti-seizure medications (ASMs) have been considered as a treatment for both disorders. This study aimed at assessing both the effectiveness of perampanel (PER) on epileptic seizures and migraine attacks in patients with epilepsy and comorbid migraine, as well as the reduction in the monthly mean rate usage of rescue migraine medications. Methods: This observational, multi-centre study included adult patients with epilepsy and comorbid migraine who started PER to better control epileptic seizures and who were followed up for 12 months. Results: Thirty-one patients were included (mean age 40.13 ± 13.13 years; 67.0% female). At the 12-month follow-up visit, 27 patients were continuing PER concomitantly with 1 (45.2%) or 2 ASMs (54.8%). A significant reduction in epileptic seizures, migraine attacks, and the monthly use of rescue migraine medications between baseline and both 6- and 12-month follow-up visits was documented. Conclusion: PER demonstrated good effectiveness in reducing both epileptic seizures and migraine attacks in patients with comorbid epilepsy and migraine. Future studies with possibly larger samples are needed to evaluate the efficacy of PER in migraine other than epilepsy.
KW - Antiseizure medication
KW - Comorbidity
KW - Epileptic seizures
KW - Follow-up
KW - Migraine attacks
KW - Rescue migraine medications
UR - http://www.scopus.com/inward/record.url?scp=85118486148&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85118486148&partnerID=8YFLogxK
U2 - 10.1016/j.yebeh.2021.108391
DO - 10.1016/j.yebeh.2021.108391
M3 - Article
AN - SCOPUS:85118486148
SN - 1525-5050
VL - 125
JO - Epilepsy and Behavior
JF - Epilepsy and Behavior
M1 - 108391
ER -